Tools
Stock profile

Praxis Precision Medicines, Inc. (PRAX)

PRAX · Latest close $305.19 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$305.19
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
2
vs previous quarter

Praxis Precision Medicines, Inc. (PRAX) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 2 funds trimming or exiting versus the previous quarter. 1 member of Congress reported 2 purchases vs 0 sales. Latest close $305.19 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
2 buys vs 0 sales
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Perceptive Advisors · Deerfield Management · Baker Bros. Advisors — 5 tracked funds hold PRAX. See all holders.

Insider and Congress activity

1 member of Congress reported buying (2 purchases vs 0 sales). Latest buy: Sep 29, 2026. Politician trading

Often held alongside

AVALYN PHARMA INC (AVLN) · RAPPORT THERAPEUTICS INC (RAPP) · Travere Therapeutics, Inc. (TVTX) · Mirum Pharmaceuticals, Inc. (MIRM) · BIOCRYST PHARMACEUTICALS INC (BCRX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Perceptive Advisors10.23%2,035,986HELD Q3 filed Nov 16
Deerfield Management3.36%963,351HELD Q3 filed Nov 16
Baker Bros. Advisors2.94%1,753,198HELD Q3 filed Nov 16
OrbiMed Advisors1.43%230,100ADDED (+33.4%) Q3 filed Nov 16
Polen Capital Management0.02%7,252TRIMMED (-27.8%) Q3 filed Nov 13
RA Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -4.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

386.3314.162024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding314 of 8,857 filers
Long-only filers among them309
Change vs 2026 Q1+24 net · 301 entered · 277 exited
Shares reported, all filers33,715,052
Reported value, all filers$11.2B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$0
Net income · FY2025$-303.3M
Total assets · FY2025$937.9M
Shares outstanding27,919,988
Market cap (at latest close)$8.5B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20263,921,934
Share of shares outstanding14.05%
Days to cover7.41

Shares short at recent settlements — Jul 31, 2026: 3.7M · Aug 14, 2026: 3.7M · Aug 31, 2026: 3.7M · Sep 15, 2026: 3.8M · Sep 30, 2026: 4.2M · Oct 15, 2026: 3.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 202626,972
Share of shares outstanding0.10%
Fails as a share of short interest · Oct 15, 20260.7%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 73 · Oct 14, 2026: 27K.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 24, 2026DeSimone JillDirector11,600$3.6MJun 24, 2026SEC filing
Nov 20, 2025Nemiroff AlexOfficer25,130$4.9MNov 20, 2025SEC filing
Nov 20, 2025Mastrocola LaurenOfficer13,600$2.6MNov 20, 2025SEC filing
Nov 14, 2024Mastrocola LaurenOfficer5,189$424.3KNov 14, 2024SEC filing
Nov 14, 2024Nemiroff AlexOfficer8,240$660.8KNov 14, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026ORBIS INVESTMENT MANAGEMENT LTDSC 13G/A1,526,6805.5%Jun 30, 2026SEC filing
May 15, 2026Baker Bros. Advisors LPSC 13G1,753,1986.3%Mar 31, 2026SEC filing
May 15, 2026ORBIS INVESTMENT MANAGEMENT LTDSC 13G/A2,468,4138.9%Mar 31, 2026SEC filing
May 15, 2026Point72 Asset Management, L.P.SC 13G/A00.0%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A2,156,343.227.7%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G1,419,3235.1%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026Perceptive Advisors LLCSC 13G/A1,995,9867.2%Dec 31, 2025SEC filing
Feb 17, 2026ORBIS INVESTMENT MANAGEMENT LTDSC 13G1,252,5735.0%Dec 31, 2025SEC filing
Feb 17, 2026Point72 Asset Management, L.P.SC 13G/A1,503,3765.9%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (2 purchases vs 0 sales). Bought by Democrats. Latest buy: Sep 29, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Cisneros, GilbertHouseD20Sep 29, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 18 Lobbying Disclosure Act filings named this company as client, 2023–2026; most common issues: Pharmacy (17), Health Issues (2).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Red Flags

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 0 · Latest buy: Sep 29, 2026

· Excess Accruals (Sloan) — Accruals ratio: 27.4% · Net income: $-303.3M · Operating cash flow: $-249.1M · Investing cash flow: $-311.1M

· Auditor Change (8-K 4.01) — Latest event: Jul 2, 2026 · Events in 2 yrs: 1

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2023 Q1, ranked #42 of 50.

Also held by the tracked funds that hold PRAX — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · RAPPORT THERAPEUTICS INC (RAPP) · Travere Therapeutics, Inc. (TVTX) · Mirum Pharmaceuticals, Inc. (MIRM) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Sionna Therapeutics, Inc. (SION) · ARROWHEAD PHARMACEUTICALS, INC. (ARWR).

Recent 8-K filings

FiledItemsSource
Nov 12, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Nov 9, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 6, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on PRAX

One email a week: the week’s new filings and research. Subscribe free

← PR  ·  PRCH →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.